FENTANYL TRANSDERMAL 25 ug/h (Fentanyl Transdermal PATCH, EXTENDED RELEASE) 25 ug/h

Fentanyl works by binding to μ-opioid receptors in the brain and spinal cord, producing analgesia by altering the perception of pain. It is an agonist at these receptors, which reduces the transmission of pain signals.

The usual dose of FENTANYL TRANSDERMAL is determined by a healthcare provider based on the patient's pain level and opioid tolerance. The patch is typically changed every 72 hours, with starting doses ranging from 12 to 25 µg/hour.

FENTANYL TRANSDERMAL is classified as a Category C drug during pregnancy, meaning it should be used with caution. It is not recommended for use during breastfeeding due to the risk of adverse effects on the infant. Always consult a healthcare provider for personalized advice.

To order FENTANYL TRANSDERMAL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

FENTANYL TRANSDERMAL is a potent opioid analgesic that is up to 100 times more potent than morphine. It is used for managing severe pain in opioid-tolerant patients. Compared to other opioids, it provides continuous pain relief through a transdermal patch, which can be advantageous for patients who have difficulty with oral medications.

FENTANYL TRANSDERMAL should be stored below 25°C, kept in the original packaging, and protected from moisture and light. Used patches should be disposed of according to the manufacturer's instructions to prevent accidental exposure.

FENTANYL TRANSDERMAL is administered via a transdermal patch that is applied to the skin. The patch should be changed every 72 hours or as directed by a healthcare provider. The patch should be applied to a clean, dry area of the skin and secured with the provided adhesive.

The most serious risks associated with FENTANYL TRANSDERMAL include respiratory depression, hypotension, seizures, and allergic reactions. Patients should be monitored closely for signs of these adverse effects, and medical attention should be sought immediately if they occur.

FENTANYL TRANSDERMAL should not be used by patients who are not opioid-tolerant, as it can cause serious respiratory depression. It should also be avoided by patients with severe respiratory conditions, such as asthma or chronic obstructive pulmonary disease (COPD), unless under strict medical supervision.